ClinicalTrials.gg

Program

Pitavastatin plus Ezetemibe

Its studies are mostly in Hypertension, led by Huons Global.

Furthest: phase 1, since Aug 5, 20261 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huons Global11 open or runningphase 1since Aug 5, 2026Aug 5, 2026Feb 2027phase 1 · NCT07784621

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2026First study: phase 1 study in HypertensionFirst studyNCT07784621 · 30 planned · South Korea

Ahead

  1. Feb 2027Primary completion: phase 1 study in HypertensionNCT07784621

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07784621Hypertension · South Korea1Not yet recruitingFeb 202730

How it is read

Names in the registry

  • “Pitavastatin plus Ezetemibe”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Pitavastatin plus Ezetemibe (Huons Global): development program | ClinicalTrials.gg